|
시장보고서
상품코드
2102272
비근침윤성 방광암 시장 규모, 점유율, 성장 분석 : 암 병기별, 리스크 카테고리별, 치료 유형별, 약물 계열별, 투여 경로별, 지역별 - 업계 예측(2026-2033년)Non Muscle Invasive Bladder Cancer Market Size, Share, and Growth Analysis, By Cancer Stage, By Risk Category, By Treatment Type, By Drug Class, By Route of Administration, By Region - Industry Forecast 2026-2033 |
||||||
세계의 비근침윤성 방광암 시장 규모는 2024년에 27억 2,000만 달러로 평가되었으며, 2025년 31억 4,000만 달러에서 2033년까지 99억 5,000만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 15.5%로 성장할 것으로 전망됩니다.
세계 비근침윤성 방광암 시장은 방광 점막 또는 점막하층에 국한된 종양의 진단, 치료 및 관리에 초점을 맞춘 다양한 제품과 서비스를 포함합니다. 방광암 사례의 대부분을 차지하는 비근침윤성 방광암(NMIBC)은 재발 빈도가 높아 지속적인 경과 관찰 및 방광 내 치료가 필요합니다. 이 시장은 칼메트-게랑균(BCG)에 대한 의존에서 벗어나, 마이토마이신 C와 같은 항암제 및 BCG에 반응하지 않는 환자를 위한 펨브롤리주맙과 같은 체크포인트 억제제를 포함한 면역요법의 최근 발전을 도입하는 방향으로 전환되고 있습니다. 이러한 전환은 인구통계학적 변화와 검출 방법의 향상을 반영하며, 환자층의 확대로 이어지고 있습니다. 약물전달 시스템의 혁신과 유리한 규제 환경에 더해 신흥 시장에서의 인지도 제고가 맞물리면서, 기존 기업과 혁신적인 생명공학 기업 모두에게 큰 성장 기회가 창출되고 있습니다.
세계 비근침윤성 방광암 시장의 성장요인
집단 검진 및 인식 제고 활동의 보급이 확대됨에 따라 방광 병변의 조기 발견이 촉진되고 있으며, 이로 인해 비근침윤성 방광암 치료 대상이 될 잠재적 환자층이 확대되고 있습니다. 이러한 노력으로 적시 진단이 가능해져 치료의 조기 시작과 임상 결과 개선으로 이어지고 있으며, 그 결과 혁신적인 방광 내 치료 및 전신 치료에 대한 수요가 유지되고 있습니다. 그 결과, 의료 종사자들은 이러한 진전에 더욱 큰 관심을 보이고 있으며, 제약사들은 제품 개발 및 시장 확대에 대한 투자를 더욱 늘리고 있습니다. 이러한 추세는 학술 기관과 산업계 간의 제휴도 촉진하고 있으며, 임상시험 피험자 등록 가속화와 새로 승인된 치료법의 지리적 보급 범위 확대로 이어지고 있습니다.
세계 비근침윤성 방광암 시장의 제약요인
세계 비근침윤성 방광암 시장은 각 지역의 제한적인 보험 급여 정책으로 인해 환자와 의료 제공자 모두에게 경제적 장벽이 발생하고 있어 큰 과제에 직면해 있습니다. 보험사가 혁신적인 치료법을 ‘비필수’로 분류하거나 낮은 환급률을 설정하면, 의료 종사자들은 이러한 치료법의 처방을 주저하고 대신 더 저렴한 대안을 선택할 가능성이 있습니다. 이러한 경제적 압박은 최첨단 제품의 시장 침투를 방해하며, 제조사들이 해당 시장에서 제품 출시를 추진하는 데 주저하게 만드는 요인이 되고 있습니다. 그 결과, 재정적 제약이 비근침윤성 방광암 분야 전체의 성장 잠재력 둔화를 초래하는 요인 중 하나가 되고 있습니다.
세계 비근침윤성 방광암 시장 동향
세계 비근침윤성 방광암(NMIBC) 시장에서는 종양 전문의들이 이러한 맞춤형 치료 접근법을 점점 더 많이 채택함에 따라 정밀 면역요법으로의 큰 전환이 진행되고 있습니다. 새로운 바이오마커의 통합을 통해 임상의는 체크포인트 억제제의 혜택을 받기 쉬운 환자를 식별할 수 있게 되어, 과잉 치료의 위험을 최소화하고 방광 보존을 우선시하면서도 장기적인 치료 성과를 향상시킬 수 있게 되었습니다. 이러한 추세는 제약사들이 면역요법과 방광 내 투여제를 결합한 혁신적인 병용요법을 개발하기 위해 연구개발 파이프라인을 추진하고 있는 점에 의해 더욱 가속화되고 있습니다. 이러한 표적화되고 침습성이 낮은 치료법이 보급됨에 따라, 시장은 전 세계적인 적응형 임상시험 설계를 통해 치료 접근성을 향상시키는 방향으로 진화하고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 비근침윤성 방광암 시장 규모 : 암 병기별
세계의 비근침윤성 방광암 시장 규모 : 리스크 카테고리별
세계의 비근침윤성 방광암 시장 규모 : 치료 유형별
세계의 비근침윤성 방광암 시장 규모 : 약물 계열별
세계의 비근침윤성 방광암 시장 규모 : 투여 경로별
세계의 비근침윤성 방광암 시장 규모 : 최종사용자별
세계의 비근침윤성 방광암 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.08.05Global Non Muscle Invasive Bladder Cancer Market size was valued at USD 2.72 Billion in 2024 and is poised to grow from USD 3.14 Billion in 2025 to USD 9.95 Billion by 2033, growing at a CAGR of 15.5% during the forecast period (2026-2033).
The global non muscle invasive bladder cancer market encompasses various products and services focused on diagnosing, treating, and managing tumors confined to the bladder mucosa or submucosa. Representing a significant portion of bladder cancer cases, NMIBC frequently recurs, necessitating ongoing surveillance and intravesical treatments. The market has shifted from reliance on Bacillus Calmette-Guerin (BCG) to incorporating chemotherapeutic agents like mitomycin C and recent advancements in immunotherapies, including checkpoint inhibitors such as pembrolizumab for BCG-unresponsive cases. This transition reflects demographic changes and improved detection methods, expanding the patient base. Innovations in drug delivery systems and favorable regulatory landscapes, coupled with rising awareness in emerging markets, present substantial growth opportunities for established companies and innovative biotech firms.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non Muscle Invasive Bladder Cancer market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Non Muscle Invasive Bladder Cancer Market Segments Analysis
Global non muscle invasive bladder cancer market is segmented by cancer stage, risk category, treatment type, drug class, route of administration, end user and region. Based on cancer stage, the market is segmented into Ta (Non-Invasive Papillary Carcinoma), T1 (Lamina Propria Invasive) and Carcinoma in Situ (CIS). Based on risk category, the market is segmented into Low-Risk NMIBC, Intermediate-Risk NMIBC and High-Risk NMIBC. Based on treatment type, the market is segmented into Surgery (Transurethral Resection of Bladder Tumor [TURBT]), Intravesical Immunotherapy, Intravesical Chemotherapy, Systemic Therapy and Radical Cystectomy. Based on drug class, the market is segmented into Bacillus Calmette-Guerin (BCG), Chemotherapeutic Agents, Immune Checkpoint Inhibitors, Gene Therapies and Others. Based on route of administration, the market is segmented into Intravesical, Intravenous and Oral. Based on end user, the market is segmented into Hospitals, Specialty Cancer Centers, Ambulatory Surgical Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Non Muscle Invasive Bladder Cancer Market
The increasing adoption of population-based screening and awareness initiatives is enhancing the early detection of bladder lesions, which broadens the potential patient base for non-muscle invasive treatments. By facilitating timely diagnoses, these efforts lead to quicker treatment starts and better clinical outcomes, thereby sustaining the demand for innovative intravesical and systemic therapies. As a result, healthcare providers show greater interest in these advancements, prompting manufacturers to invest more in product development and market growth. This dynamic also encourages partnerships between academic institutions and industry, leading to faster clinical trial enrollment and an expanded geographical distribution for newly approved treatments.
Restraints in the Global Non Muscle Invasive Bladder Cancer Market
The Global Non-Muscle Invasive Bladder Cancer market faces significant challenges due to restrictive reimbursement policies in various regions, which create financial obstacles for both patients and healthcare providers. When insurance companies categorize innovative therapies as non-essential or provide them with low reimbursement rates, healthcare professionals may hesitate to prescribe these treatments, opting instead for more affordable options. This economic pressure hampers the penetration of cutting-edge products and dissuades manufacturers from focusing on product launches in these markets. As a result, fiscal constraints contribute to a slowdown in the overall growth potential of the non-muscle invasive bladder cancer sector.
Market Trends of the Global Non Muscle Invasive Bladder Cancer Market
The Global Non-Muscle Invasive Bladder Cancer (NMIBC) market is experiencing a significant shift towards precision immunotherapy, as oncologists increasingly embrace this tailored approach to treatment. The integration of emerging biomarkers enables clinicians to identify patients who are likely to benefit from checkpoint inhibitors, minimizing the risk of overtreatment and enhancing long-term outcomes while prioritizing bladder preservation. This trend is further fueled by pharmaceutical companies advancing their research and development pipelines to create innovative combination therapies that incorporate immunotherapy with intravesical agents. As these targeted, less invasive solutions gain traction, the market is evolving to enhance access through adaptive clinical trial designs on a global scale.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Non Muscle Invasive Bladder Cancer Market Size by Cancer Stage & CAGR (2026-2033)
- Market Overview
- Ta (Non-Invasive Papillary Carcinoma)
- T1 (Lamina Propria Invasive)
- Carcinoma in Situ (CIS)
Global Non Muscle Invasive Bladder Cancer Market Size by Risk Category & CAGR (2026-2033)
- Market Overview
- Low-Risk NMIBC
- Intermediate-Risk NMIBC
- High-Risk NMIBC
Global Non Muscle Invasive Bladder Cancer Market Size by Treatment Type & CAGR (2026-2033)
- Market Overview
- Surgery (Transurethral Resection of Bladder Tumor [TURBT])
- Intravesical Immunotherapy
- Intravesical Chemotherapy
- Systemic Therapy
- Radical Cystectomy
Global Non Muscle Invasive Bladder Cancer Market Size by Drug Class & CAGR (2026-2033)
- Market Overview
- Bacillus Calmette-Guerin (BCG)
- Chemotherapeutic Agents
- Immune Checkpoint Inhibitors
- Gene Therapies
- Others
Global Non Muscle Invasive Bladder Cancer Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Intravesical
- Intravenous
- Oral
Global Non Muscle Invasive Bladder Cancer Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Specialty Cancer Centers
- Ambulatory Surgical Centers
- Others
Global Non Muscle Invasive Bladder Cancer Market Size & CAGR (2026-2033)
- North America (Cancer Stage, Risk Category, Treatment Type, Drug Class, Route of Administration, End User)
- US
- Canada
- Europe (Cancer Stage, Risk Category, Treatment Type, Drug Class, Route of Administration, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Cancer Stage, Risk Category, Treatment Type, Drug Class, Route of Administration, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Cancer Stage, Risk Category, Treatment Type, Drug Class, Route of Administration, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Cancer Stage, Risk Category, Treatment Type, Drug Class, Route of Administration, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Merck & Co. Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson Services Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ferring Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Asieris Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Photocure ASA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Olympus Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Karl Storz SE & Co KG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ipsen S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viatris Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz International GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
